Mouwasat Medical Services (4002) Fundamentals 2026 — P/E 14.5x, Revenue Analysis | SniperIQ
Mouwasat Medical Services (4002) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 12.0B, trading at SAR 60.00 on the SAU. This SniperIQ fundamentals page covers Mouwasat Medical Services's valuation (P/E 14.5x, P/B 3.0x), profitability (net margin 25.1%), revenue (SAR 3.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mouwasat Medical Services's market cap?
Mouwasat Medical Services (4002) has a market capitalization of approximately SAR 12.0B, trading at SAR 60.00 on the SAU. Market cap moves with the live share price.
What is Mouwasat Medical Services's P/E ratio?
Mouwasat Medical Services's trailing twelve-month P/E ratio is 14.5x, with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mouwasat Medical Services?
Mouwasat Medical Services runs a net profit margin of 25.1%, a gross margin of 41.2%, and an operating margin of 26.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mouwasat Medical Services generate?
Mouwasat Medical Services reported revenue of SAR 3.2B for fiscal year 2025, with net income of SAR 822M and earnings per share (EPS) of 4.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mouwasat Medical Services pay a dividend?
Mouwasat Medical Services offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Mouwasat Medical Services financially healthy?
Mouwasat Medical Services carries a debt-to-equity ratio of 0.29x and a current ratio of 1.62x, with a market beta of 0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mouwasat Medical Services a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mouwasat Medical Services (4002) the key facts are: market cap SAR 12.0B, P/E 14.5x, revenue SAR 3.2B, 52-week range 58.65-79.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mouwasat Medical Services's full fundamentals live
Get Mouwasat Medical Services's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.